Given the known beneficial effect of mineralocorticoid receptor antagonists on E/e ́ ratio[23] and subsequent reduction in hospitalization for heart failure[24], the reduction in E/e ́ ratio observed in the EmDia trial is of specific interest in the context of the beneficial effect of empagliflozin in patients with heart failure and preserved ejection fraction with and without diabetes mellitus [25]. This evidence concerns the gene NR3C2 and heart failure.